Pregabalin

Green-G

Brand Name(s):Lyrica

Indication:Neuropathic pain

Rationale:

Considered:Oct-04

Review Date:Mar-26

Comments:
Updated guidance MHRA February ’21:

*pregabalin has been associated with reports of respiratory depression, in some cases without concomitant opioid treatment
*consider whether adjustments in dose or dosing regimen are necessary for patients at higher risk of respiratory depression, this includes people: *with compromised respiratory function, respiratory or neurological disease, or renal impairment
*taking other CNS depressants (including opioid-containing medicines)
*aged older than 65 years

SPC update – sections 4.4 and 4.5 advise caution when used with opioids due to risk of CNS depression – this increased risk was observed at low doses of pregabalin (? 300 mg) and there was a trend for a greater risk at high doses of pregabalin.

NICE CG 173
management of Neuropathic Pain information at:http://www.nice.org.uk/nicemedia/live/14301/65756/65756.pdf
Issued November 2013